Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology
- Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales
- Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapies
- Enhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 years
- Ambition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of Dupixent and Vaccines
Paris, December 6, 2023. Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.
Focusing on its unprecedented portfolio of 12 new molecular entities with blockbuster potential, including multiple late-stage assets, the company will be prioritizing development and leveraging its leadership in immunology across all other therapeutic areas. Sanofi will also share its ambitions to break efficacy ceilings and expand into new indications, generating a steady flow of predominantly wholly-owned new assets.
The company will continue to serve more patients with a combination of strong growth from existing assets and a steady stream of potential blockbuster launches:
- Pharma assets - Recently launched and future pharma assets are expected to generate over €10 billion of annual sales by 2030, driven by late-stage pipeline assets such as amlitelimab, frexalimab, itepekimab, and tolebrutinib, as well as recently launched products including ALTUVIIIO®, Sarclisa®, and Tzield®.
- Dupixent® - Expected to continue its strong performance and to deliver a low double-digit net sales growth CAGR from 2023 to 2030, supported by expected new indications such as chronic obstructive pulmonary disease (COPD) as well as greater penetration in approved indications.
- Vaccines - Sanofi reiterates its expectation to generate over €10 billion of annual sales by 2030, including the recent launch of Beyfortus®.
Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Houman Ashrafian, Head of Research and Development, Sanofi
“Today we show how our decision to strategically increase our focus on R&D will unlock our pipeline’s full potential as we prioritize potential first- or best-in-class assets to deliver innovative medicines to patients. With an unprecedented number of potential blockbuster assets in our pipeline, we will showcase how we become a development-driven, tech-powered biopharma company, committed to serving patients and accelerating growth. We are in a privileged position today with many very promising assets in mid- and late-stage development. We believe in our capacity to improve outcomes for patients globally, while bringing innovative new medicines to market and strengthening our leadership in immunology and neuro-inflammation.”
Paul Hudson, Chief Executive Officer, Sanofi
“Building on our successful recent launches, we are making decisive choices to deliver breakthrough medicines and long-term value for all of our stakeholders. We are confident in our current product portfolio and the strength of our pipeline to deliver sustainable growth through 2030 and beyond. I could not be prouder of the progress we have made over the past three years, and I am looking forward to sharing further updates as our key assets pass new milestones toward their market launch and as we turn Sanofi into an immunology powerhouse.”
Highlighted key programs
Sanofi shares insights into the development status and target indications of its pipeline of 12 potential blockbuster assets in immunology and vaccines. This includes its three ‘pipeline-in-a-product’ assets, amlitelimab, frexalimab and SAR441566 (Oral TNFR1si), each with a peak sales potential of over €5 billion, as well as treatments for multiple sclerosis (tolebrutinib), asthma (lunsekimig, rilzabrutinib), inflamatory bowel disease (Anti-TL1A), atopic dermatitis (IRAK4 degrader), and COPD (itepekimab). Additional potential blockbusters include vaccines against acne, extraintestinal pathogenic E. coli, and RSV in older adults.
The company also demonstrates strong proof points of its progress in increasing R&D productivity, notably by continuously evolving its R&D engine, unlocking the power of its data and leveraging AI at scale to inform portfolio decisions. Additionally, Sanofi presents the actions taken to reflect the group’s sustainability roadmap across its development pipeline.
Speakers, Webcast and Materials
Speakers at the event include over a dozen members of the Sanofi leadership and R&D teams, including CEO Paul Hudson and Head of R&D Houman Ashrafian. Investors will also hear physicians’ perspectives on multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD), two major development areas for Sanofi.
A live webcast of the R&D Day presentations will start at 8:30 a.m. U.S. Eastern Time (2:30 p.m. Paris time) and supporting slide materials will be available on Sanofi’s investor relations website at 7:30 a.m. U.S. Eastern Time (1:30 p.m. Paris time). The webcast will conclude at 12:45 p.m. U.S. Eastern Time (6:45 p.m. Paris time). A replay of the live webcast will be available after the event.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Sandrine Guendoul | + 33 6 25 09 14 25 | firstname.lastname@example.org
Sally Bain | + 1 617 834 6026 | email@example.com
Victor Rouault | + 33 6 70 93 71 40 | firstname.lastname@example.org
Evan Berland | +1 215 432 0234 | email@example.com
Nicolas Obrist | + 33 6 77 21 27 55 | firstname.lastname@example.org
Eva Schaefer-Jansen | + 33 7 86 80 56 39 | email@example.com
Arnaud Delépine | + 33 6 73 69 36 93 | firstname.lastname@example.org
Corentine Driancourt | + 33 6 40 56 92 21 | email@example.com
Felix Lauscher | + 1 908 612 7239 | firstname.lastname@example.org
Tarik Elgoutni| + 1 617 710 3587 | email@example.com
Nathalie Pham | + 33 7 85 93 30 17 | firstname.lastname@example.org
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r
Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release
Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of the delisting procedure and consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a
798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release
BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release
Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,